



“Providing an opportunity for multiple myeloma patients and their loved ones to come together to exchange information for mutual support, comfort, and friendship”

Meeting: **In person meetings will resume when we are allowed to gather at the address below.**

451 Junction Road
Madison, WI
UW West Clinic Room 1287

Enter the clinic... turn left and walk down a short hall...turn left again and conference room 1287 is the last one on the left.

Group Information:

Jayne Schwartz 608- 244-2120
schwartzdon@sbcglobal.net

Madison Multiple Myeloma Support Group website
madisonmultiplemyeloma.org

Mailing Address: Wisconsin Multiple Myeloma Support Group
3309 Chicago Avenue Madison, WI 53714-1815

Information Sources :

International Myeloma Foundation (IMF)
Phone: 800 - 452 - 2873
Email: TheIMF@myeloma.org
Website: www.myeloma.org

Multiple Myeloma Research Foundation(MMRF)
Phone: 203 - 972 - 1250
Email: info@themmrf.org
Website: www.multiplemyeloma.org

Myeloma Crowd /Health Tree Foundation
P.O. Box 1286
Draper, UT 84020
www.myelomacrowd.org

February 2022 Myeloma Newsletter

Upcoming Meeting Speakers-

Shannon Ramirez, Oncology Clinical Educator from the Janssen Pharmaceutical Company will be our featured speaker for the March 15, 2022 meeting. Her presentation will be the “Shared Decision Making Deck”. Shannon will present from 3:30pm to 4:30pm.

Dr Aric Hall from the UW Carbone Cancer Center will be available for the April 19th meeting. He will do his usual Q & A session. Mark your calendars now so you don't miss this meeting. He will join us at 4:30pm.

Working on the May meeting to feature someone from the IMF InfoLine. More information to follow.

Dr Timothy Schmidt, UW Carbone Cancer Center will be out featured speaker for the July 19th meeting. He will be presenting information related to chromosomes and genetics.

Kimberly A. Gibbs RN, BSN, OCN., Patient Advocacy Liaison from Takeda Oncology will be our featured speaker for the August meeting. Topic to be determined later.

For the February Meeting....

Cameron Ninos, UW Pharmacist will be our featured speaker for the February 15, 2022 virtual meeting. It will be an open discussion for questions related to medications. **This will not be a forum for questions about pricing.** Cameron will present from 4:00pm to 5:00pm.

Newest Publication from the IMF in printed booklet format and PDF format available now.

Understanding ABECMA® (idecabtagene vicleucel)

Abecma® (idecabtagene vicleucel, “ide-cel”) is the first-in-class BCMA-directed CAR T-cell immunotherapy approved by the U.S. Food and Drug Administration for use in myeloma. Abecma is a personalized immune cell therapy delivered as a one-time infusion, manufactured for each individual patient using the patient’s own white blood cells. The digital version of the booklet is available for viewing and downloading at the IMF website.

The Master trial has generated a lot of interest and exciting results.

ASH 2021: One Step Closer to Chemo Free Living?

Achieving a prolonged minimal residual disease (MRD) standard after consolidation may raise hope for a chemo-free future for patients who respond well to therapy and liberate them from maintenance according by Dr. Luciano Costa, from the University of Alabama at Birmingham.

The MASTER trial proposed modifying post autologous stem cell transplant (ASCT) consolidation and maintenance; to make them dependent on the depth of response achieved, with up to 80% of patients qualifying for treatment-free observation.

Patients who achieved MRD negativity entered treatment-free observation (known as MRD-SURE) with continued MRD monitoring for recurrence. Those who did not become MRD-SURE entered lenalidomide maintenance.

Separating newly diagnosed (NDMM), transplant-eligible patients according to their number of high-risk cytogenetic features (HRCA), ranging from zero to two or more, all patients received induction Dara-KRd (daratumumab, carfilzomib, lenalidomide, dexamethasone), followed by transplant. This combination resulted in an unprecedented depth of response in NDMM patients, as measured by minimal residual disease MRD status.

Decisions about modification and/or possible cessation of therapy was dependent upon the depth of response, as measured by MRD. Following transplant, patients received Dara-KRd as consolidation therapy.

The number of cycles of consolidation therapy patients received was dictated by their MRD status, was checked frequently, which was a novel approach. Patients continued on consolidation until they tested MRD negative (at 10⁻⁵) on two consecutive tests or until the consolidation phase ended (eight cycles of Dara-KRd).

Dr. Costa's team sought to define the most appropriate post-ASCT consolidation therapy. Overall, 71% of patients achieved MRD-SURE status and progression free survival rates were 91%, 97%, 58% for patients with 0, 1 and 2+ high risk features, respectively.

The MASTER trial has been, and continues to be, a treasure trove of data for the newly diagnosed myeloma patients. Certainly, the DARA-KRD induction, followed by ASCT, has shown an unprecedented depth of response.

While the MASTER data does not qualify observation only as a current standard of care, it does offer hope that there may be a maintenance free future for a significant percentage of newly diagnosed myeloma patients.

Our virtual meetings are on the Zoom platform.

Our meeting for February 15, 2022 will be from 3:30pm to 5:00pm featuring Cameron Ninos, UW pharmacist.

Join Zoom Meeting

<https://myeloma-org.zoom.us/j/84457667535?pwd=V0lJTdNQ2FOZ1hMUkFaRmJBc0Qzdz09>

Meeting ID: 844 5766 7535

Passcode: 678275

One tap mobile

+13017158592,,84457667535#,,,,*678275# US (Washington DC)

+13126266799,,84457667535#,,,,*678275# US (Chicago)

Dial by your location

+1 301 715 8592 US (Washington DC)

+1 312 626 6799 US (Chicago)

+1 646 558 8656 US (New York)

+1 253 215 8782 US (Tacoma)

+1 346 248 7799 US (Houston)

+1 669 900 9128 US (San Jose)

Meeting ID: 844 5766 7535

Passcode: 678275

Find your local number: <https://myeloma-org.zoom.us/j/kyMbCRs05>

IMF Info Line – If you or someone you care for has Myeloma, you have questions. Probably, lots of them. You can search the Internet all you want, but other than asking your doctor, there is no better way to get your questions answered than to call the IMF Info Line. Missy, Judy and Paul know their stuff and they want to share what they know with you. Just ask anyone who has called the IMF Info Line. Patients or caregivers are welcome to contact the Info Line staffed by trained specialists at 800-452-CURE (800-452-2873). The Info Line is staffed between 9am and 4pm Pacific Time, 11am to 6pm Central time or infoline@myeloma.org.

The Trillium Fund was established by our founding support group members to facilitate Multiple Myeloma research here in Madison at the Wisconsin Institute of Medical Research. If you or your family wish to donate or send a memorial to this program, checks can be made payable to the “UW Foundation – Trillium Fund” and sent to UW Carbone Cancer Center, University of Wisconsin Foundation, 1848 University Ave, Madison, WI 53726. Donations may also be made online at www.supportuw.org/give (Trillium Fund in Multiple Myeloma Research – 112903576). For any questions, please call Daniel Rosen at (608) 264-5437 or email curecancer@supportuw.org.